Advertisement

Related Videos

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Amit Sanyal, MD: A Clinician’s Perspective

Advertisement

Advertisement




Feb
26
Today In Oncology
Intravesical Immunotherapy Shows Recurrence Control in BCG-Unresponsive Papillary-Only Non–Muscle-Invasive Bladder Cancer
Gemcitabine Intravesical System Shows High Disease-Free Survival Rates in BCG-Unresponsive Papillary-Only NMIBC
FDA Approves Encorafenib for Metastatic BRAF V600E–Mutated Colorectal Cancer
MRI-Based Neoadjuvant Chemotherapy Duration in HER2-Positive Breast Cancer
Can a New Testing Method Allow More Patients With Bladder Cancer to Avoid Radical Cystectomy
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo